Data backs Pear Therapeutics digital therapeutic for opioid use disorder

Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT).

Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD).

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pear Therapeutics reports positive real-world data for chronic insomnia treatment

Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT).

Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Digital therapeutics open up new opportunities in medicine

Pear Therapeutics designed the reSET prescription digital therapeutic for the treatment of substance abuse disorder. [Image courtesy of Pear Therapeutics]A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar said via email. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthc…

Read more
  • 0

Digital therapeutics open up new opportunities in medical design

A wide range of companies are aiming to make waves through digital therapeutic offerings and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar told Medical Design & Outsourcing. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthcare.” 

Read: How DeepWell is developing video games as tools for treating me…

Read more
  • 0

FDA grants STeP designation for Pear Therapeutics’ neurobehavioral digital therapeutic

Pear Therapeutics (Nasdaq:PEAR) announced today that it received STeP designation from the FDA for its Pear-010 product candidate.

Boston-based Pear Therapeutics designed its Pear-010 prescription digital therapeutic (PDT) candidate to provide a neurobehavioral intervention (virtual reality-delivered pain reduction) to patients 18 and older with acute postoperative and acute postprocedural pain.

The company said in a news release that it plans to utilize its PearCreate discovery and development platform to develop the Pear-010 PDT.

FDA’s Safer Technologies Program (STeP) voluntary program exists for certain medical devices and device-led combination products that are reasonably expected to significantly improve the safety of currently available treatments and diagnostics.

The goal of STeP is to provide patients and healthcare providers with timely access to such devices by expediting their development, assessment and review while maintaining…

Read more
  • 0

Pear Therapeutics launches program to offer digital therapeutics through telehealth platforms

Pear Therapeutics (Nasdaq:PEAR) announced today that it launched a program to offer digital therapeutic users access to a telehealth provider.

Boston-based Pear’s program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool,” as well as in-person care options.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pear Therapeutics posts massive Q4 revenue uptick as product sales increase

Pear Therapeutics (Nasdaq:PEAR) missed Wall Street’s fourth-quarter revenue projections despite a major year-over-year increase in sales.

The Boston-based prescription digital therapeutic (PDT) developer posted profits of $18.8 million, or 13¢ per share, on sales of $1.2 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain from losses of nearly $48 million this time last year as revenues grew from just $34,000 in that period.

Pear Therapeutics’ earnings per share of 13¢ came in 54¢ ahead of projections on Wall Street, where analysts were looking for sales of $1.5 million.

The company attributed its uptick in sales compared to the fourth quarter of 2020 primarily due to product sales of Pear’s three FDA-authorized products.

“We showed strong execution in 2021, with the company reaching its first commercial inflection point, highlighted by our rapid progress on provider adoption and payor access for our …

Read more
  • 0

Pear Therapeutics joins Epic App Orchard to enable monitoring of its digital therapeutics

Pear Therapeutics (Nasdaq:PEAR) announced today that its PearConnect platform is now available in the Epic App Orchard Gallery.

By making PearConnect available to healthcare providers through the Epic App Orchard Gallery, the providers who implement the application will be able to access PearConnect within Epic’s leading electronic health record (EHR) platform, allowing them to monitor patients who have been prescribed Pear’s prescription digital therapeutics (PDTs).

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pear Therapeutics to develop digital therapeutic for sleep/wake disorder in Japan

Pear Therapeutics (Nasdaq:PEAR) announced today that it entered an agreement to develop a Japanese-language digital therapeutic.

Boston-based Pear struck a deal with SoftBank, a Japan-based communication and information technology service provider, to develop the digital therapeutic for the treatment of sleep/wake disorders on the Japanese market.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pear Therapeutics says new data backs its prescription digital therapeutic for insomnia

Pear Therapeutics (Nasdaq:PEAR) today announced data from two studies that highlight the effectiveness of its chronic insomnia treatment.

Boston-based Pear Therapeutics designed its Somryst prescription digital therapeutic (PDT) to address the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), training the body to sleep. The nine-week PDT can be used on a mobile device, such as a smartphone or tablet as the only FDA-authorized therapeutic that delivers guideline-recommended first-line treatment for chronic insomnia.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pear Therapeutics advances in efforts to get CMS to cover prescription digital therapeutics

Pear Therapeutics (NSDQ:PEAR) announced that the Centers for Medicare & Medicaid Services (CMS) established new coding relevant to its prescription digital therapeutics (PDTs).

CMS established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe prescription digital behavioral therapy — FDA-cleared — per course of treatment, which extends to PDTs including Pear’s reSET, reSET-O and Somryst.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pear Therapeutics closes SPAC merger, lists on Nasdaq

Pear Therapeutics today began trading on the Nasdaq market following the completion of a previously announced merger at the end of last week.

Boston-based Pear confirmed in June that it would go public by merging Thimble Point Acquisition Corp., a special purpose acquisition company (SPAC). Following approval from Thimble Point’s stockholders at the end of last month, the company announced the completion of the merger on Friday.

Today, Pear Therapeutics officially began trading on the Nasdaq market under the “PEAR” ticker. The transaction generated approximately $175 million in gross proceeds in total. Pear said it would use the funds to capitalize its position as a leader in software for treating serious disease.

Pear Therapeutics develops prescription digital therapeutics (PDTs) and currently has three authorized by the FDA for treating substance use disorder, opioid use disorder and chronic insomnia. Its alcohol use disorder treatmen…

Read more
  • 0